Autolus Therapeutics plc (NASDAQ:AUTL) Shares Bought by HighVista Strategies LLC

HighVista Strategies LLC lifted its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 98.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 518,820 shares of the company’s stock after purchasing an additional 257,496 shares during the quarter. HighVista Strategies LLC owned about 0.20% of Autolus Therapeutics worth $1,805,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in AUTL. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics in the 2nd quarter worth about $43,000. Bayesian Capital Management LP purchased a new stake in Autolus Therapeutics during the 1st quarter worth $100,000. Daiwa Securities Group Inc. increased its holdings in Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after purchasing an additional 15,293 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Autolus Therapeutics during the first quarter worth about $108,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Autolus Therapeutics in the first quarter worth about $127,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AUTL shares. Needham & Company LLC reiterated a “buy” rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research note on Monday, June 17th. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research note on Monday, June 3rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Autolus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $8.70.

Autolus Therapeutics Price Performance

Shares of AUTL stock opened at $3.73 on Monday. The firm has a fifty day moving average of $4.09 and a two-hundred day moving average of $4.39. The firm has a market cap of $992.31 million, a P/E ratio of -3.11 and a beta of 2.05. Autolus Therapeutics plc has a 1-year low of $2.01 and a 1-year high of $7.45. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, research analysts anticipate that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.